153 employees
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
2017
$440M
from 5 investors over 5 rounds
Laronde raised $440M on August 30, 2021
Investors: The Invus Group, T. Rowe Price, Longevity Vision Fund and Flagship Ventures
Laronde raised $50M on May 10, 2021
Investors: Flagship Ventures